Novel Therapies for the treatment of cancer.

Our present objective is to continue to create and develop novel drugs and devices for the management of cancer. Our lead therapeutic agents are DM-CHOC-PEN and hydroperoxy analogs.

Company Profile

DEKK-TEC was formed in 1983, and has utilized government and private funding to effectively develop new therapies and clinical development candidates for the treatment of cancer, pre-cancerous lesions, and women's health issues. We have previously licensed two of our pipeline products to Biotech/Pharmaceutical companies who have successfully driven these compounds into Phase II clinical development. We also have experience with 510K devise submissions.

Our present objective is to continue to create and develop new and novel drugs based on our current novel cancer therapeutic agents - DM-CHOC-PEN and hydroperoxy analogs.

Industry Sector: PHARMACEUTICALS

Target Market(s) Oncology — (CNS and metastatic stage solid tumors)

Focus on developing new concepts for the management of cancer and allied diseases

Key Value Drivers

Technology

Novel anti-cancer agents able to cross the blood brain barrier.

Competitive Advantage

DM-CHOC-PEN is our lead proprietary investigational anticancer agent with the specific advantage of being able to cross the blood brain barrier and localize in cancer tissue. Many cancer drugs do not cross the blood brain barrier and must be given intra-cranially where they cause significant toxicity with only modest efficacy. DM-CHOC-PEN can be given intravenously because it does cross the blood brain barrier, with superior efficacy to available therapies in pre-clinical studies. The product has favorable safety, toxicity and PK/PD profiles. As such, DM-CHOC-PEN represents a significant new cancer therapy opportunity to address a large unmet medical need.

Current Plan & Strategy

IV DM-CHOC-PEN is currently in phase I studies in patients with primary brain cancer and CNS metastases refractory to the current standards of care and is well tolerated to date

Adolescent and Young Adults (AYA) vs. Adult Subjects with Advanced Malignancies Involving the CNS Differences in Responses to Anticancer Drugs Malignancies of the central nervous systems (brain and spinal cord) occur at every age level of human life; no age group is spared the possibility of developing a primary or secondary central nervous system (CNS) malignancy. [...]

One of our products – isophosphoramide mustard (IPM) – that was licensed to ZIOPHARM Oncology, Inc. – now known as ‘Palifosfamide’ is moving nicely in Phase III trials. DEKK-TEC was awarded a US patent 7,678,778 for drug composition of matter and the concept. A recent presentation, which received a ‘PICASSO’ award, can be viewed by [...]